Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rational for and avenues toward a green pharmacy

Environmental Health Perspectives

Volumn 111, Issue 5, 2003, Pages 757-774

  Daughton, Christian G ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cradle to cradle stewardship; Drugs; Environmental pollution; Green pharmacy; Pollution prevention

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CHOLINESTERASE INHIBITOR; COSMETIC; ESOMEPRAZOLE; ESTROGEN; GESTAGEN; GROUND WATER; LEVALBUTEROL; MORPHINE; NALTREXONE; NEW DRUG; OMEPRAZOLE; OPIATE ANTAGONIST; SALBUTAMOL; SURFACE WATER; THALIDOMIDE; XENOBIOTIC AGENT;

ARTICLE; CONSUMER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG PACKAGING; DRUG POTENCY; DRUG QUALITY; DRUG RELEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; HEALTH CARE INDUSTRY; HEALTH HAZARD; HEALTH PROMOTION; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACY; POLLUTANT; POLLUTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUSPENDED PARTICULATE MATTER; WASTE DISPOSAL; WATER QUALITY; WATER SUPPLY;

ANIMALIA;

EID: 0038187641     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.5947     Document Type: Article

References (153)

1. Abramowicz M (ed). 2002. Drugs past their expiration date, Med Lett (On Drugs and Therapeutics) 44(W114B):93-94. Available: http://www.medletter.com/freedocs/expdrugs.pdf [accessed 10 May 2002].
2. ACS. 2002. Future Directions of Drug Delivery Technologies: Molecular Design, Cellular Response and Nanotechnology. American Chemical Society ProSpectives Conference Series, 13-16 October 2002, Boston, MA. Available: http://www.acsprospectives.org [accessed 3 September 2002].
3. Active Health Management. 2002. Evidence Based Medicine. New York: Active Health Management, Inc. Available: http://www.activehealthmanagement.com/treatingphys.asp [accessed 28 July 2002].
4. Alliance Pharmaceutical. 2002. Drug Formulation Technology for Compounds Administered by Inhalation. San Diego, CA:Alliance Pharmaceutical Corp. Available: http://www.allp.com/PulmoSpheres/PS_WHITE.HTM [accessed 10 May 2002].
5. Alper J. 2002. Breaching membranes. Science 296:838-839.
6. AMA. June 2001. Report 1 of the Council on Scientific Affairs (A-01): Pharmaceutical Expiration Dates. AMA Policy H-115.983. Chicago:American Medical Association. Available: http://www.ama-assn.org/ama1/upload/ mm/interim01/CSA_Reports.pdf [accessed 10 May 2002].
7. Arole R. 2001. Community based health and development: the Jamkhed experience. Health Promotion J Austral 11(1):5-9.
8. Arroll B, Kenealy T, Kerse N. 2002. Do delayed prescriptions reduce the use of antibiotics for the common cold? A single-blind controlled trial. J Fam Pract 51(4):324-328.
9. ASCE. 2001. 2001 The 2001 Report Card for America's Infrastructure. Washington, DC:American Society of Civil Engineers. Available: http://www.asce.org/reportcard [accessed 10 May 2002].
10. Biocode. 2002. Applications: Pharmaceuticals. Bethlehem, PA:Biocode. Available: http://www.biocode.com/ [accessed 10 May 2002].
11. Blutstein H. 2003. A forgotten pioneer of sustainability. J Cleaner Prod 11:(3):339-341.
12. Borman S. 2002. In situ click chemistry. Chem Eng News 80(6):29-34. Available: http://pubs.acs.org/cen/coverstory/ 8006/8006clickchemistry.html [accessed 10 May 2002].
13. Bradley D. 2002. Computational toxicology. Alchemist, 6 June. Available: http://www.chemweb.com/alchem/articles/ 1022229169054.html? [accessed 11 June 2002].
14. Buchanan M. 2001. Ubiquity: The Science of History ... or Why the World Is Simpler Than We Think. New York:Three Rivers Press.
15. Buhner SH. 2002. The Lost Language of Plants: The Ecological Importance of Plant Medicines to Life on Earth. White River Junction, VT:Chelsea Green Publishing.
16. CDC. 2002. Promoting Appropriate Antibiotic Use in the Community. Atlanta, GA:Centers for Disease Control and Prevention. Available: http://www.cdc.gov/drugresistance/ community/ [accessed 10 May 2002].
17. CHI. 2002. -Omes and -Omics Glossary. Newton Upper Fall, MA:Cambridge Healthtech Institute. Available: http:// www.genomicglossaries.com/content/omes.asp [accessed 10 May 2002].
18. COMPAS. March 2002. F&DA Environmental Assessment Regulations Project Benchmark Survey. A Report to Health Canada. POR-02-13. Ottawa, Ontario, Canada:Office of Regulatory and International Affairs, COMPAS Inc. Available: http://www.hc-sc.gc.ca/ear-ree/fda_report_e.pdf [accessed 3 July 2002].
19. Crain SM, Shen K-F. 2001. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 888(1):75-82.
20. CRS. 2002. Home page. Minneapolis, MN:Controlled Release Society. Available: http://www.geriatrictimes.com/ g010709.html [accessed 3 September 2002].
21. Crutchfield DB. 2001. Patients respond to lower doses of medications. Geriatr Times 2(4). Available: http://www. geriatrictimes.com/g010709.html [accessed 10 May 2002].
22. CSTEE. 2001. Opinion on: Draft CPMP Discussion Paper on Environmental Risk Assessment of Medicinal Products for Human Use [Non-Genetically Modified Organism (Non-GMO) Containing]. 24th Scientific Committee on Toxicity, Ecotoxicity and The Environment (CSTEE) plenary meeting, 12 June 2001, Brussels, Belgium. Available: http://europa.eu.int/ comm/food/fs/sc/sct/out111_en.pdf [accessed 10 May 2002].
23. CVM. 2002. NARMS: National Antimicrobial Resistance Monitoring System. Rockville, MD:U.S. FDA Center for Veterinary Medicine. Available: http://www.fda.gov/cvm/index/narms/narms_pg.html [accessed 10 May 2002].
24. Cyveillance. 5 June 2001. Cyveillance Partners with Biocode to Serve Pharmaceutical Industry [press release]. Arlington, VA:Cyveillance, Inc.
25. Daughton CG. 2001a. Pharmaceuticals in the environment: overarching issues and overview. In: Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (Daughton CG, Jones-Lepp T, eds). Symposium series 791. Washington DC:American Chemical Society, 2-38. Available: http://www.epa.gov/ nerlesd1/chemistry/pharma/book-summary.htm [accessed 10 May August 2002].
26. Daughton CG. 2001b. Literature forensics? Door to what was known but now forgotten. Environ Forensics 4(2):277-282. Available: http://www.epa.gov/nerlesd1/chemistry/pharma/images/for ensics.pdf [accessed 10 May 2002].
27. Daughton CG. 2001c. Illicit drugs in municipal sewage: proposed new non-intrusive tool to heighten public awareness of societal use of illicit/abused drugs and their potential for ecological consequences. In: Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (Daughton CG, Jones-Lepp T, eds). Symposium series 791. Washington DC:American Chemical Society, 348-364. Available: http://www.epa.gov/ nerlesd1/chemistry/pharma/book-conclude.htm [accessed 10 May 2002].
28. Daughton CG. 2002a. Environmental stewardship and drugs as pollutants. Lancet 360:1035-1036.
29. Daughton CG. 2002b. Literature forensics: navigating through flotsam, jetsam, and lagan. Scientist 16(4):12. Available: http://www.the-scientist.com/yr2002/feb/opin_020218.html [accessed 10 May 2002].
30. Daughton CG. 2003. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environ Health Perspect 111:775-785.
31. Daughton/U.S. EPA. 2001. Commentary on Illicit Drugs in the Environment: A Tool for Public Education - Societal Drug Abuse and Its Aiding of Terrorism. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/pharma/ book-post.htm [accessed 10 May 2002].
32. Daughton/U.S. EPA. 2002a. Pharmaceuticals and Personal Care Products (PPCPs) as Environmental Pollutants: Pollution from Personal Actions, Activities, and Behaviors. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/pharma/index.htm [accessed 10 May 2002].
33. Daughton/U.S. EPA. 2002b. Summary of Media Coverage Regarding PPCPs in the Environment. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/ nerlesd1/chemistry/ppcp/media.htm [accessed 10 May 2002].
34. Daughton/U.S. EPA. 2002c. Origins and Fate of PPCPs in the Environment. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/pharma/images/drawing.pdf [accessed 10 May 2002].
35. Daughton/U.S. EPA. 2002d. The Precautionary Principle ("Reverse Onus"). Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/ppcp/ relevant.htm#ThePrecautionaryPrinciple [accessed 10 May 2002].
36. Daughton/U.S. EPA. 2002e. Perspectives from the Pharmaceutical Industry and Examples of Corporate Stewardship Programs. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/ppcp/ relevant.htm#Perspective [accessed: 14 August 2002].
37. Daughton/U.S. EPA. 2002f. Antibiotics: Prudent/Judicious Use. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/ppcp/relevant.htm# antibiotics [accessed 10 May 2002].
38. Daughton/U.S. EPA. 2002g. Factors Complicating Prediction of Drug Elimination from the Body. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http:// www.epa.gov/nerlesd1/chemistry/images/slides/part3.pdf [accessed 10 May 2002].
39. Daughton/U.S. EPA. 2002h. Disposal and New Ideas in PPCP Recycling and Pollution Prevention. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/ nerlesd1/chemistry/ppcp/relevant.htm#Disposal [accessed 10 May 2002].
40. Daughton/U.S. EPA. 2002i. Confined Animal Feeding Operations. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/nerlesd1/chemistry/ppcp/relevant.htm #Confined Animal Feeding Operations [accessed 10 May 2002].
41. Daughton/U.S. EPA. 2003a. Biological Systems and Stressors. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://wws.epa.gov/nerlesd1/chemistry/ppcp/stressors.htm [accessed 13 April 2003].
42. Daughton/U.S. EPA. 2003b. Environmental Stewardship of PPCPs: The Green Pharmacy. Las Vegas, NV:U.S. Environmental Protection Agency. Available: http://www.epa.gov/ nerlesd1/chemistry/ppcp/greenpharmacy.htm [accessed 3 April 2003].
43. Daughton CG, Jones-Lepp T, eds. 2001. Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues. Symposium Series 791. Washington DC:American Chemical Society. Available: http://www.oupusa.org/isbn/0841237395.html [accessed 10 May 2002].
44. Daughton CG, Ternes TA. 1999. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect 107(suppl 6):907-938. Available: http://www.epa.gov/nerlesd1/chemistry/ppcp/images/ errata.pdf [accessed 10 May 2002].
45. Disability Resources.org. 2002. Prescription Drug Assistance Programs. Centereach, NY:Disability Resources.org. Available: http://www.disabilityresources.org/RX.html [accessed 10 May 2002].
46. Duke University. 2002. Medicine and Madison Avenue. Available: http://scriptorium.lib.duke.edu/mma [accessed 10 May 2002].
47. EMEA. 2001. Draft CPMP Discussion Paper on Environmental Risk Assessment of Non-Genetically Modified Organism (Non-GMO) Containing Medicinal Products for Human Use. CPMP/SWP/4447/00 draft corr. London:The European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use. Available: http:// www.emea.eu.int/pdfs/human/swp/444700en.pdf [accessed 7 June 2002].
48. Epel D, Smital T. 2001. Multidrug/multixenobiotic transporters and their significance with respect to environmental levels of pharmaceuticals and personal care products. In: Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (Daughton CG, Jones-Lepp T, eds). Symposium series 791. Washington, DC:American Chemical Society, 244-263.
49. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. 2002. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 359:1648-1654.
50. Express Scripts. 2001. Prescription Drug Atlas. Maryland Heights, MO:Express Scripts Inc. Available: http://www.expressscripts.com/other/news_views/outcomes_research/ atlas2002/atlas_ex_sum.htm [accessed 10 May 2002].
51. Facts and Comparisons. 2002. Drugfacts.com, Facts and Comparisons. St. Louis, MO:Facts and Comparisons. Available: http://www.drugfacts.com/shop.asp [accessed 2 June 2002].
52. Fernandez-Lopez S, Kim H-S, Choi EC, Delgado M, Granja JR, Khasanov A, at al. 2002 Antibacterial agents based on the cyclic d,l-α-peptide architecture. Nature 412:452-455.
53. Fong PP. 2001. Antidepressants in aquatic organisms: a wide range of effects. In: Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (Daughton CG, Jones-Lepp T, eds). Symposium series 791. Washington DC:American Chemical Society, 264-281.
54. Gallbally R. December 2000, National Competition Review of Drugs, Poisons and Controlled Substances Legislation. Final Report Part A, Wodan, ACT:Commonwealth of Australia. Available: http://www.health.gov.au/tga/ docs/pdf/rdpfina.pdf [accessed 10 May 2002].
55. Genaissance Pharmaceuticals. 2002. Personal Medicine from Genomics. New Haven, CT:Genaissance Pharmaceuticals. Available: http://www.genaissance.com/home_index.html [accessed 10 May 2002].
56. Gibson T. 2002. The innovation imperative. Environ Forum, March/April, 23-31. Available: http://www.epa.gov/ opei/eli2002mar.pdf [accessed 10 May 2002].
57. Gleick J. 1987. Chaos: Making a New Science. New York:Viking Penguin.
58. Green JV, Murray BH. 2001. Online Distribution of Counterfeit Pharmaceuticals. Arlington, VA:Cyveillance, Inc. Available: http://www.cyveillance.com/web/downloads/Online_Pharmaceuticals.pdf [accessed 10 May 2002].
59. E. 2002. Memorandum of Understanding: EPA-AHA. Washington, DC:Hospitals for a Healthy Environment. Available: http://www.h2e-online.org/about/mou.htm [accessed 16 July 2002].
60. Handley DA, Tinkelman D, Noonan M, Rollins TE, Snider ME, Caron J. 2000. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 37(4):319-327.
61. Harremoës P, Gee D, MacGarvin M, Stirling A, Keys J, Wynne B, et al., eds. 2001. Late Lessons from Early Warnings: The Precautionary Principle 1896-2000. Environmental issue report no. 22. Copenhagen:Office for Official Publications of the European Communities. Available: http://reports.eea.eu.int/environmental_issue_report_2001_22/ an [accessed 10 May 2002].
62. Health Canada. 2002. Environmental Assessment Regulations (EAR): Food and Drug Products and the Environment. Ontario, Canada:Environmental Assessment Regulations Project. Available: http://www.hc-sc.gc.ca/ear-ree/index_e.html [accessed 10 May 2002].
63. Heberer T. 2002. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data, Toxicol Lett 131(1-2):5-17.
64. Holling CS. 1986. The resilience of terrestrial ecosystems: local surprise and global change. In: Sustainable Development of the Biosphere {Clark WC, Munn RE, eds). Cambridge, UK:Cambridge University Press, 292-317.
65. Intralytix. 2002. Bacteriophage Research & Development. Baltimore, MD:Intralytix, Inc. Available: http://www. intralytix.com [accessed 10 May 2002].
66. IOM. 2001. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC:Committee on Quality of Health Care in America, Institute of Medicine, National Academy Press. Available: http://www.nap.edu/books/ 0309072808/html [accessed 2 June 2002].
67. ISTS. 2002. Initiative on Science and Technology for Sustainability. Cambridge, MA:Belfer Center for Science and International Affairs, Kennedy School of Government, Harvard University. Available: http:// sustsci.harvard.edu/index.html [accessed 4 September 2002].
68. JRCAB. 2002. DOD/FDA Shelf Life Extension Program. Joint Readiness Clinical Advisory Board, U.S. Department of Defense. Available: http://www.jrcab.army.mil/fda/ page1.html [accessed 10 May 2002].
69. Kohn LT, Corrigan JM, Donaldson MS, eds. 2000. To Err Is Human: Building a Safer Health System. Washington, DC:Committee on Quality of Health Care in America, Institute of Medicine, National Academy Press. Available: http://www.nap.edu/books/0309068371/html [accessed 2 June 2002].
70. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, et al. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol 36:1202-1211.
71. Kümmerer K, ed. 2001 Pharmaceuticals in the Environment - Sources, Fate, Effects and Risks. Heidelberg, Germany:Springer-Verlag Heidelberg. Available: http://www. epa.gov/nerlesd1/chemistry/pharma/kummer/default.htm [accessed 20 May 2002].
72. Landis WG. 2002. Uncertainty in the extrapolation from individual effects to impacts upon landscapes. Human Ecol Risk Assess 8(1):193-204.
73. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 279:1200-1205.
74. Lee SB, Mitchell DT, Trofin L, Nevanen TK, Söderlund H, Martin CR. 2002. Antibody-based bio-nanotube membranes for enantiomeric drug separations. Science 296:2198-2200.
75. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23(1-3):3-25.
76. Lipsitch M, Singer RS, Levin BR. 2002. Antibiotics in agriculture: when is it time to close the barn door? Proc Natl Acad Sci USA 99(9):5752-5754.
77. Lorenz E. 1963. Deterministic nonperiodic flow. J Atmos Sci 20:130-141.
78. Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, Crinelli R, et al. 2002. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Therapy 9(11):749-751.
79. Martinovic D, Schoenfuss HL, Sorensen PW. 2003. Exposure to low levels of water-borne estrogen suppresses the competitive spawning ability of male fathead minnows. In: Proceedings of the 3rd International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water. Minneapolis, MN:National Ground Water Association, 125-132.
80. MBDC. 2002. Transforming Industry: Cradle to Cradle Design. Charlottesville, VA:McDonough Braungart Design Chemistry. Available: http://www.mbdc.com/c2c_home.htm [accessed 10 May 2002].
81. McDonough W, Braungart M. 2002. Cradle to Cradle - Remaking the Way We Make Things. New York:North Point Press.
82. McGovern SL, Caselli E, Grigorieff N, Shoichet, BK. 2002. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45(8):1712-1722. Available: http://pubs.acs.org/cgibin/jcen?jmcmar/asap/html/jm010533y.html [accessed 10 May 2002].
83. Meek C. November 2001. Direct-to-consumer advertising of prescription medicines: a review of international policy and evidence. Supplement to a report for the Royal Pharmaceutical Society of Great Britain. London:Royal Pharmaceutical Society of Great Britain. Available: http://www.rpsgb.org.uk/pdfs/dtcarev.pdf [accessed 10 May 2002].
84. Miller M. 2002. Breaking down barriers. Science 297:1116-1118.
85. MIT 3DPTM Laboratory. 2002. Three Dimensional Printing. Cambridge, MA: Massachusetts Institute of Technology. Available: http://web.mit.edu/tdp/www/medical.html [accessed 10 May 2002].
86. MIT News. 1997. MIT Scientists "Print" Drugs Into Pills. 13 April [press release]. Cambridge, MA:Massachusetts Institute of Technology. Available: http://web.mit.edu/ newsoffice/nr/1997/43521.html [accessed 10 May 2O02].
87. Mort M. 2000. Multiple modes of drug delivery. Mod Drug Discov 3(3):30-32,34. Available: http://pubs.acs.org/ hotartcl/mdd/00/apr/mort.html [accessed 10 May 2002].
88. Munoz-Bellido JL, Munoz-Criado S, Garcìa-Rodrìguez JA. 2000. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J Antimicrob Agents 14(3):177-180.
89. NABP. 2002. Verified Internet Pharmacy Practice Sites. Park Ridge, IL:National Association of Boards of Pharmacy. Available: http://www.nabp.net/vipps/intro.asp [accessed 4 June 2002].
90. National Health Council. 2002. Direct-To-Consumer Prescription Drug Advertising. National Health Council statement. Washington, DC:National Research Council. Available: http://www.nhcouncil.org/advocacy/dtc.htm [accessed 10 May 2002].
91. National Research Council. 2001. Grand Challenges in Environmental Sciences; Committee on Grand Challenges in Environmental Sciences. Oversight Commission for the Committee on Grand Challenges in Environmental Sciences, Washington DC:National Academy Press. Available: http://www.nap.edu/books/0309072549/html [accessed 10 May 2002].
92. National Research Council. 2002a. Oil in the Sea III: Inputs, Fates, and Effects. Washington, DC:National Academy Press. Available: http://www.nap.edu/books/0309084385/html [accessed 29 May 2002).
93. National Research Council. 2002b. Biosolids Applied to Land: Advancing Standards and Practices. Washington, DC:National Research Council. Available: http://www.nap.edu/books/0309084865/html [accessed 3 August 2002].
94. NCSE. 2001. Recommendations for Achieving Sustainable Communities: Science and Solutions. A Report from the Second National Conference on Science, Policy, and the Environment, 6-7 December 2001. Washington, DC:National Council for Science and the Environment. Available: http://cnie.org/ncseconference/2001 conference/report/ 2001nfport.pdf; http://cnie.org/ncseconference/ 2001conference/report/page.cfm?FID = 1692 [accessed 29 May 2002].
95. NHLBI. 2002. Facts about Postmenopuasal Hormone Therapy. Bethesda, MD:National Heart, Lung, and Blood Institute, National Institutes of Health. Available: http:// www.nhlbi.nih.gov/whi/hrtupd/index.htm [accessed 4 June 2002].
96. Nuovo J, Melnikow J, Chang D. 2002. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 287:2813-2814. Available: http:// jama.ama-assn.org/cgi/reprint/287/21/2813.pdf [accessed 10 June 2002].
97. Odum WE. 1982. Environmental degradation and the tyranny of small decisions. Bioscience 32(9):728-729. Available: http://www.netspace.net.au/~jnevill/Tyranny_of_small_decisions.doc [accessed 10 May 2002].
98. Okeke CC. 2002. Current USP requirements and proposals on packaging systems. Am Pharm Outsourcing 3(2):34-38.
99. ONDCP. 2002. Drugs and Terror. Rockville, MD:Office of National Drug Control Policy, National Youth Anti-Drug Media Campaign. Available: http://www.theantidrug.com/drugs_terror/index.html [accessed 10 May 2002].
100. Orchid Biosciences. 2002. Profiling Genetic Uniqueness. Princeton, NJ:Orchid Biosciences. Available: http:// www.orchid.com [accessed 10 May 2002].
101. OSU. 2000a. Prescription Medicines and Nursing Homes: A Problem ... a Solution. Health and Medicine issue paper. Tulsa, OK:Oklahoma State University College of Osteopathic Medicine. September. Available: http:// www.healthsciences.okstate.edu/telemedicine/Pub/chpr/ chpr.0009.pdf [accessed 25 July 2002]
102. OSU. September 2000b. Prescription Medicines & Nursing Homes: Laws - Letters - Reports - Policies. An Issue Paper Resource Supplement. Tulsa, OK:Oklahoma State University College of Osteopathic Medicine. Available: http://www.healthsciences.okstate.edu/telemedicine/Pub/ chpr/chpr.0009a.pdf [accessed 25 July 2002].
103. Pain Therapeutics. 2002. Pain Therapeutics. South San Francisco, CA:Pain Therapeutics, Inc. Available: http:// www.paintrials.com/index.html [accessed 10 May 2002].
104. PDR. 2002a. 2002 Physicians' Desk Reference. 56th ed. Montvale, NJ:Thomson Medical Economics.
105. PDR. 2002b. Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements, 23rd ed.Montvale, NJ:Thomson Medical Economics.
106. Phillips KA, Veenstra DL, Oren E. 2001. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279.
107. PhRMA. 2003. Direct-to-Consumer Advertising Archives. Washington, DC:Pharmaceutical Research and Manufacturers of America. Available: http://www.phrma.org/ mediaroom/press/index.cfm?archive=DtoCAds [accessed 3 April 2003].
108. Pyxis. 2002. Pyxis. San Diego, CA:Pyxis Corp. Available: http://www.pyxis.com [accessed 10 May 2002].
109. Quintiles. 2000. Quintiles Launches Commercial Version of Rx Market Monitor. Durham, NC:Quintiles Transnational Corp. Available: http://www.quintiles.com/pressrelease [accessed 10 May 2002].
110. Quintiles. 2002. Quintiles. Durham, NC:Quintiles Transnational Corp. Available: http://www.quintiles.com [accessed 10 May 2002].
111. Rapport DJ. 2002. The health of ecology and the ecology of health. Human Ecol Risk Assess B(1):205-213.
112. RCBC. 2002. Zero Waste. Vancouver, British Columbia, Canada:Recycling Council of British Columbia. Available: http://www.rcbc.bc.ca/zerowaste/zerowaste.htm [accessed 10 May 2002].
113. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. 2002. Promotion of prescription drugs to consumers. N Engl J Med 346:498-505.
114. Saffel D. 1999. Improving outcomes, managing drug costs, and achieving success under PPS. Consultant Pharmacist 14(6). Available: http://www.ascp.com/public/pubs/tcp/1999/ jun/improving.shtml [accessed 10 May 2002].
115. Schneider SH, Turner BL. 1994. Surprise and Global Environmental Change: Report of the 1994 Aspen Global Change Institute Summer Session on Surprise and Global Environmental Change. Thematic Guide to Integrated Assessment Modeling, Draft 3.0. University Center, MI:Center for International Earth Science Information Network. Available: http://sedac.ciesin.org/mva/ iamcc.tg/articles/surprise.html [accessed 10 May 2002].
116. Schowanek D, Webb S. 2002. Exposure simulation for pharmaceuticals in European surface waters with GREAT-ER. Toxicol Lett 131(1-2):39-50.
117. Servos MR, Innes E, Given J, Ostapyk K, Topp E, McInnis R, et al. 2002. Assessment and Management of Pharmaceutcals and Personal Care Products in the Canadian Environment: Proceedings of a Multi-stakeholder Workshop. Environment Canada and Health Canada Special Publication. NWRI Contribution 02-334. Burlington, Ontario, Canada:National Water Research Institute, Environment Canada. Available (Executive Summary of Proceedings): http://www.nwri.ca/announce/pharmaceuticals-e.html [accessed 2 August 2002).
118. SkyePharma. 2003. Solubilization. London:SkyePharma PLC. Available: www.skyepharma.com/solubilization.com [accessed 1 April 2003].
119. Slovic P. 2001. The risk game. J Hazard Matter 86(1-3):17-24.
120. Smith CA. 1999. Rationale for inclusion of criteria for proper disposal of monograph pharmaceutical preparations based on the Resource Conservation and Recovery Act. Pharm Forum 25(3):8309-8312.
121. Smith DL, Harris AD, Johnson JA, Silbergeld EK, Morris JG Jr. 2002. Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria [Abstract]. Proc Natl Acad Sci USA 99(9):6434-6439. Available: http://www.pnas.org/cgi/ content/abstract/082188899v1 [accessed 10 May 2002].
122. Straub JO. 2002. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Toxicol Lett 131(1-2):137-143.
123. Thornton J. 2000. Beyond risk: an ecological paradigm to prevent global chemical pollution. Int J Occup Environ Health 6(4):318-330.
124. TNS. 2002. The Natural Step. San Francisco, CA:The Natural Step. Available: http://www.detnaturligasteget.se [accessed 27 June 2002].
125. Toma T. 2001. Cathelicidin and dermicin are antimicrobial proteins that enhances skin defense against invasive bacteria. Philadelphia, PA:The Scientist.com. Available: http://www.biomedcentral.com/news/20011123/03 [accessed 10 May 2002].
126. Toxicology Letters. 2002. Toxicol Lett 131(1-2):1-146 [Abstracts]. Available: http://www.elsevier.com/locate/toxlet?menu = cant&label = Table [accessed 16 August 2002].
127. UNEP. 2002. Industry as a Partner for Sustainable Development - 10 Years after Rio: The UNEP Assessment. Paris:United Nations Environment Programme. Available: http://www.uneptie.org/outreach/wssd/docs/global/UNEP_report-english.pdf [accessed 6 June 2002].
128. Urine Town. 2002. Home page. Greg Kotis (playright); John Rando (director); Mark Hollmann (score). Available (description): http://www.urinetown.com/flash/home_1a.html [accessed 10 May 2002].
129. U.S. DHHS. July 1998. Guidance for Industry Environmental Assessment of Human Drug and Biologics Applications. CMC 6, Revision 1. Rockville, MD:U.S. Department of Health and Human Services. Available: http://www.fda.gov/cber/ gdlns/environ.pdf [accessed 10 May 2002].
130. U.S. EPA. 2000. U.S. EPA Strategic Plan. EPA 190-R-00-002. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa-gov/ocfopage/plan/plan.htm [accessed 10 May 2002].
131. U.S. EPA. 2002. Innovation for Better Environmental Results: Innovating a Strategy to Guide the Next Generation of Innovation at EPA. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa.gov/ opei/strategy [accessed 10 May 2002].
132. U.S. EPA Office of Pesticide Programs. 1996. Reduced Risk, IPM and Pollution Prevention. Washington, DC:U.S. Environmental Protection Agency. Available: http:// www.epa.gov/oppfead1/fqpa/rripmpp.htm [accessed 10 May 2002].
133. U.S. EPA Office of Pollution Prevention and Toxics. 2002. EPA's Green Chemistry Program. Washington, DC:U.S. Environmental Protection Agency. Available: http:// www.epa.gov/greenchemistry [accessed 10 May 2002].
134. U.S. EPA Office of Wastewater Management. 2002a. Combined Sewer Overflows. Washington, DC:U.S. Environmental Protection Agency. Available: http://cfpub.epa.gov/npdes/home.cfm?program_id=5 [accessed 10 May 2002].
135. U.S. EPA Office of Wastewater Management. 2002b. A Plain English Guide to the EPA Part 503 Biosolids Rule. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa.gov/OWOWM.html/mtb/biosolids/503pe/index.htm [accessed 10 May 2002].
136. U.S. EPA Office of Water - Ground Water and Drinking Water. 2002. Unregulated Contaminant Monitoring Rule. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa.gov/safewater/ucmr.html [accessed 10 May 2002].
137. U.S. EPA Science Policy Council. 2002. Interim Genomics Policy. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa.gov/osp/spc/genomics.htm [accessed 5 August 2002].
138. U.S. FDA. 2001. Guidance for Industry - Q1A Stability Testing of New Drug Substances and Products. Revision 1. Rockville, MD:U.S. Food and Drug Administration. Available: http://www.fda.gov/cder/guidance/4282fnl.htm [accessed 10 May 2002].
139. U.S. FDA. 2002a. Buying Medicines and Medical Products Online.Rockville, MD:U.S. Food and Drug Administration. Available: www.fda.gov/oc/buyonline [accessed 10 May 2002].
140. U.S. FDA. 2002b. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Rockville, MD:U.S. Food and Drug Administration. Available: http://www.fda.gov/ medwatch/ [accessed 10 May 2002].
141. U.S. FDA. 2002c. The New Over-the-Counter Medicine Label: Take a Look. Rockville, MD:Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Available: http://www.fda.gov/cder/consumerinfo/OTClabel.htm [accessed 10 May 2002].
142. USGS. 2002. USGS Toxic Substances Hydrology Program: What's in Our Wastewaters and Where Does it Go? Denver, CO:U.S. Geological Survey. Available: http://toxics.usgs.gov/ highlights/whatsin.html [accessed 10 May 2002].
143. USP. 2001. A USP Council of Experts Statement of Scientific Policy - Guiding Principles Supporting Appropriate Drug Use at the Patient and Population Level. Rockville, MD:U.S. Pharmacopeia, 12 March 2001. Available: http://www.usp.org/information/drug_principle.pdf [accessed 10 May 2002].
144. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615-2623.
145. Velagaleti R, Burns PK, Gill M, Prothro, J. 2002. Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal. Environ Health Perspect 110:213-220.
146. Velagaleti R, Gill M. 2001 regulatory oversight for the environmental assessment of human and animal health drugs: environmental assessment regulations for drugs. In: Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (Daughton CG, Jones-Lepp T, eds). Symposium series 791. Washington DC:American Chemical Society, 320-332.
147. Wackernagel M, Rees W. 1995. Our Ecological Footprint: Reducing Human Impact on the Earth. Philadelphia, PA:New Society Publishers.
148. WHO. 1999. Guidelines for Safe Disposal of Unwanted Pharmaceuticals in and after Emergencies. Geneva:World Health Organization. Available: http://www.who.int/medicines/library/par/who-edm-par-99-2/who-edm-par-99-2.htm [accessed 10 May 2002].
149. WHO. 2001. World Water Day Report 2001: Water for Health - Taking Charge. Geneva:World Health Organization. Available: http://www.worldwaterday.org/2001/report/index.html; http://www.worldwaterday.org/2001/report/wwdreport.pdf [accessed 10 May 2002].
150. WHO. 2002a. Global Assessment of the State-of-the-Science of Endocrine Disruptors (Damstra T, Barlow S, Bergman A, Kavlock R, Kraak, GVD, eds), WHO/PCS/EDC/02.2. Geneva:International Programme on Chemical Safety. Available: http://www.who.int/pcs/emerg_site/edc/ global_edc_TOC.htm [accessed 13 August 2002].
151. WHO. 2002b. WHO Policy and Strategy on Traditional Medicine. Essential Drugs and Medicines Policy. Geneva:World Health Organization. Available: http:// www.who.int/medicines/organization/trm/ orgtrmmain.shtml [accessed 18 May 2002].
152. World's Water. 2002. Information on the World's Freshwater Resources. Oakland, CA:Pacific Institute. Available: http://www.worldwater.org/links.htm [accessed 10 May 2002].
153. XenoPort. 2002. Home page. Santa Clara, CA: XenoPort, Inc. Available: http://www.xenoport.com/ [accessed 10 May 2002].